Treatment with anti-erbb2 antibodies
CA 2311409 C · Owner: Genentech, Inc. · Inventors: Hellmann, Susan D.; Shak, Steven; Paton, Virginia E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically the invention concerns the , treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline e.g. doxorubicin or , epirubicin.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 10, 1998 and granted April 12, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 10, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 10, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.